Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360° In its 5th year, the IO360 conference brings together diverse stakeholders of drug development in immuno-oncology (IO). The
Xconomy: New York Biotech – How to make it here
6:15-6:45 PM | The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team with multiple clinical programs and $40M in Series C funding, our executives tell the story of our Manhattan-based biotechnology company. Masoud Tavazoie - CEO,
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute